A blueprint for better cholesterol-lowering drugs

May 10, 2001



May 11, 2001
--A better strategy for developing more effective cholesterol-lowering drugs may come from the first studies of the structural mechanism by which the widely prescribed statin drugs, such as Lipitor and Zocor, lower cholesterol.

In an article published in the May 11, 2001, issue of the journal Science, Howard Hughes Medical Institute (HHMI) investigator Johann Deisenhofer at the University of Texas Southwestern Medical Center, and colleague Eva S. Istvan, reported x-ray crystallography data that show how six different statin compounds fit into the active site of the enzyme HMG-CoA reductase (HMGR). HMGR catalyzes a key step in cholesterol production.

After making crystals of the HMGR protein bound to each of the statins, Deisenhofer and Istvan then passed a beam of x-rays through the crystals. By analyzing the pattern of diffraction created as the X-rays bounce off atoms in the crystals, the scientists deduced the three-dimensional structures of the drugs bound to HMGR.

Deisenhofer and Istvan found that statins bind to HMGR's active site--the catalytic region of enzymes that binds biological substances--and prevent the enzyme from producing a molecule that is crucial to cholesterol synthesis. The studies also showed that statins do not block an additional region of HMGR's active site, suggesting that there is room for improvement. Statins that target HMGR more effectively might prove better at reducing the enzyme's activity.

Deisenhofer and Istvan studied compactin (also known as mevastatin), simvastatin (Zocor), fluvastatin (Lescol), cerivastatin (Baycor), atorvastatin (Lipitor), and rosuvastatin (Crestor). Simvastatin and two others not studied--lovastatin (Mevacor) and pravastatin (Pravachol)--closely resemble compactin, which is not in clinical use.

"Although there is room for improvement in these drugs," said Deisenhofer, "there is no desperate need because the known inhibitors work quite well."

Deisenhofer emphasized that he and his colleagues undertook these studies to learn more about how the cholesterol-synthesis pathway works at the molecular level. "It was clear that statins compete with one of the substrates for binding to the enzyme," said Deisenhofer. "But it was not known whether all the compounds bind the same way and what they do to the structure of the enzyme."

The scientists divided the statins into two groups based on their structure. Type 1 statins included lovastatin, pravastatin and simvastatin; and type 2 statins included fluvastatin, cerivastatin, atorvastatin, and rosuvastatin.

"They are structurally quite different," said Istvan, who was formerly a graduate student in Deisenhofer's laboratory and is now postdoctoral fellow in the laboratory of HHMI investigator Daniel Goldberg at Washington University School of Medicine in St. Louis. "Type 1 statins are generally smaller and have a smaller surface area and fewer interactions with HMGR," she said. "The type 2 inhibitors are larger and form more interactions with the enzyme's active site. While all the compounds inhibit the enzyme well, the type 2 statins have more interactions with the active site and appear to be better inhibitors."

One of the most significant findings, said Istvan, was that the statins do more than just compete with the normal substrate in the enzyme's active site. They also alter the conformation of the enzyme when they bind to its active site. This prevents HMGR from attaining a functional structure. "The change in conformation at the active site, which we didn't understand before, makes these drugs very effective and specific," said Istvan.

Istvan and Deisenhofer found that none of the statins affected a second important region of the HMGR enzyme. "From the structures we determined, there is an indication that new statins might be developed that occupy a second pocket close to the active site that is now unoccupied by the existing drugs," Istvan said. The unoccupied pocket is the portion of the enzyme that binds a second substrate--an energy-containing molecule called NADPH that drives the enzyme's catalytic reaction.

"It might be possible to produce a more specific drug that fits into both of these pockets and interacts even more tightly with the enzyme," said Istvan.

Deisenhofer emphasized, however, that tight binding of statins to the enzyme might not be the whole story. "The suspicion is that the effects of the statins stem not just from their inhibition of HMGR, but from interactions with other completely different proteins," he said. "There is very little known about these possible interactions, and there may be some surprises out there in the bush waiting for us that might make a big difference in the clinical effects of different statins." Reports in the scientific literature indicate that statins can also affect blood vessel growth, bone formation and the immune system, said Deisenhofer.

Howard Hughes Medical Institute

Related Statins Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Twitter data research reveals more about what patients think about statins
More than one in seven people taking statins -- prescribed to lower cholesterol levels -- believed that meant they could still eat unhealthy foods, a new study shows.

Statins starve cancer cells to death
More than 35 million Americans take statin drugs daily to lower their blood cholesterol levels.

Statins linked to higher diabetes risk
Individuals who take cholesterol-lowering statins may be at higher risk for developing high blood sugar levels, insulin resistance, and eventually type 2 diabetes, according to an analysis published in the British Journal of Clinical Pharmacology.

Statins could protect against motor neurone disease
High cholesterol has been found to be a possible risk factor for the development of motor neurone disease (MND), according to a large study of genetic data led in the UK by Queen Mary University of London, in collaboration with the National Institutes of Health in the USA.

Statins are more effective for those who follow the Mediterranean diet
For those who have already had a heart attack or a stroke, the combination of statins and Mediterranean Diet appears to be the most effective choice to reduce the risk of mortality, especially from cardiovascular causes.

Statins have low risk of side effects
Cholesterol-lowering statin drugs are associated with a low risk of side effects.

Statins overprescribed for primary prevention
Taking cholesterol-lowering drugs, or statins, as a preventive measure can reduce the risk of cardiovascular disease.

Many older adults do not take prescribed statins properly
In a British Journal of Clinical Pharmacology study of older adults prescribed statins, first-year nonadherence and discontinuation rates were high.

Statins show little promise for conditions other than heart disease
Medicines commonly prescribed to reduce people's risk of heart attack may have limited use for treating other diseases, research suggests.

Read More: Statins News and Statins Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.